Financial Times Examines Implications Of Controversy Over Indian HPV Vaccination Study

The Financial Times examines how the deaths of seven female participants of a study on the cost and feasibility of incorporating human papillomavirus (HPV) vaccines “into India’s public sector immunization program” has affected opinions of drug trials in the country. “[T]he program to vaccinate 14,000 adolescent girls from poor families ran into trouble after seven died soon after their vaccinations,” the newspaper notes. Though “[t]he causes of the girls’ deaths were never established or conclusively linked to the HPV vaccine … serious questions were raised over whether the participants’ parents — many of whom were illiterate — had given informed consent, and whether the project adequately tracked any adverse reactions,” the newspaper writes, adding, “The ensuing media and political storm — highlighting sensitivities around drug trials in the developing world — has contributed to the restrictions on such studies, affecting both Indian and global pharmaceutical companies” (Kazmin, 11/18).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.